Quick Answer
Mereo BioPharma Group plc reported Net Income Loss of -$41.88 million for the year ending 2025.
- Mereo BioPharma Group plc showed an increase of +3.2% in Net Income Loss from 2024 to 2025.
- This data is from Mereo BioPharma Group plc's annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Mereo BioPharma Group plc's Net Income Loss has grown by 0.8%.
- Historical annual values: Fiscal year 2025: -$41.88 million | Fiscal year 2024: -$43.25 million | Fiscal year 2023: -$29.47 million | Fiscal year 2022: -$42.22 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: